iOnctura to present late-breaking data on roginolisib in immunotherapy-resistant NSCLC at SITC
- Data from the ongoing PULMO-01 clinical study to be presented on November 6, 2026, at SITC 2026
- Roginolisib is the first conformation-selective PI3Kδ inhibitor that locks the enzyme in its inactive state
Geneva, Switzerland and Amsterdam, The Netherlands and Cambridge, Massachusetts, USA, October 29, 2026 – iOnctura today announced that a late-breaking poster evaluating roginolisib in patients with immunotherapy-resistant non-small cell lung cancer (NSCLC) will be presented at the Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting, taking place November 4-8 in Phoenix, Arizona.
